In Q2 2025, ORIC Pharmaceuticals posted a net loss of $21.4 million with no revenue as it continues to focus on advancing its clinical-stage oncology programs. The company reported a decrease in R&D expenses compared to the prior year and ended the quarter with $233.6 million in cash and investments.

ORIC Pharmaceuticals reported a net loss of $30.021 million for the first quarter of 2025, with total assets of $242.858 million and cash and investments of $223.8 million. The company made significant progress in its pipeline, including focused registrational development plans for its lead programs, ORIC-944 and ORIC-114, and extended its cash runway into 2027.

ORIC Pharmaceuticals reported a net loss of $36.307 million for Q4 2024, an increase from $28.330 million in Q4 2023. The company's cash and investments totaled $256 million, expected to fund operations into late 2026. Key achievements included progress in ORIC-114 and ORIC-944 clinical trials, strategic partnerships, and successful financing.

ORIC Pharmaceuticals reported cash and investments of $282.4 million, expected to fund the operating plan into late 2026. The company continues to advance ORIC-114 and ORIC-944 programs towards registrational studies. Clinical collaborations were announced to support the ORIC-944 trial in combination with AR inhibitors for prostate cancer.

ORIC Pharmaceuticals reported cash and investments of $308.5 million, which is expected to fund operating plan into late 2026. The company is advancing its pipeline with ORIC-114 and ORIC-944, and expanded its leadership team.

ORIC Pharmaceuticals reported its Q1 2024 financial results, highlighting progress in clinical and preclinical programs and a strengthened cash position with $331.5 million in cash, cash equivalents, and investments. The company expects this to fund operations into late 2026. Key programs ORIC-114 and ORIC-944 are advancing towards potential registrational studies.

ORIC Pharmaceuticals reported a net loss of $28.33 million for the fourth quarter of 2023. The company's cash, cash equivalents, and investments totaled $235.0 million as of December 31, 2023, which is expected to fund the operating plan into late 2026.

ORIC Pharmaceuticals reported its Q3 2023 financial results, highlighting progress across its pipeline, including the presentation of initial Phase 1b data for ORIC-114, and steady enrollment across its three clinical trials. The company's cash and investments are expected to fund operations into late 2025.

ORIC Pharmaceuticals reported its second quarter 2023 financial results, highlighting steady enrollment in its three clinical trials and the completion of an $85 million private placement financing, ending the quarter with $273.7 million in cash and investments.

ORIC Pharmaceuticals reported cash and investments of $208.9 million, expected to fund the operating plan into the first half of 2025. The company is advancing its novel oncology pipeline, with initial Phase 1b data expected in the second half of 2023 for three ongoing clinical trials.

ORIC Pharmaceuticals reported its fourth quarter and full year 2022 financial results, highlighting progress across its clinical pipeline and a $25 million equity investment from Pfizer. The company anticipates initial Phase 1b data for three ongoing clinical trials in the second half of 2023 and expects its cash and investments to fund operations into the first half of 2025.

ORIC Pharmaceuticals reported its Q3 2022 financial results, highlighting the FDA clearance of the US IND for ORIC-114 and the upcoming presentation of ORIC-533 preclinical data at the ASH Annual Meeting. The company's cash and investments are expected to fund operations into 2H 2024.

ORIC Pharmaceuticals reported its Q2 2022 financial results, highlighting a strong cash position of $237.8 million expected to fund operations into 2H 2024, and progress in its clinical programs with initial data expected in 1H 2023.

ORIC Pharmaceuticals reported its Q1 2022 financial results, highlighting progress in its pipeline of novel oncology candidates and the expectation to report initial data from three ongoing studies in the first half of 2023. The company's cash and investments are expected to fund its current operating plan into 2H 2024.

ORIC Pharmaceuticals discontinued the development of ORIC-101 after interim analyses showed insufficient clinical activity. The company will now focus on advancing its three single agent Phase 1 programs and expects to report initial data in the first half of 2023. With cash and investments of $280.4 million, the company's cash runway is extended into the second half of 2024.

ORIC Pharmaceuticals reported its Q3 2021 financial results, highlighting the advancement of its pipeline, including initial clinical data from the ORIC-101 Phase 1b trial and preclinical data on ORIC-114. The company's cash and investments of $296.5 million are expected to fund operations into 2024.

ORIC Pharmaceuticals reported its Q2 2021 financial results, highlighting the initial data readout for ORIC-101 in combination with nab-paclitaxel and the FDA clearance of the IND application for ORIC-533. The company's cash and investments totaled $305.9 million, expected to fund operations into 2024.

ORIC Pharmaceuticals reported its first quarter 2021 financial results, highlighting the advancement of its oncology pipeline with upcoming data readouts and IND/CTA filings. The company's cash reserves are expected to fund operations into the second half of 2023.

ORIC Pharmaceuticals reported its Q4 and full-year 2020 financial results, highlighting the progress of its pipeline, team expansion, and strengthened balance sheet. The company's lead program, ORIC-101, is on track for initial data readouts in 2021, and three IND/CTA filings are expected for ORIC-533, -944, and -114. With $293.6 million in cash, cash equivalents, and investments, ORIC expects to fund operations into the second half of 2023.

ORIC Pharmaceuticals reported its Q3 2020 financial results, highlighting the expansion of its precision oncology pipeline through in-licensing agreements and the advancement of its lead program, ORIC-101, towards multiple interim data readouts in 2021. The company also anticipates filing IND/CTAs for ORIC-533, ORIC-944, and ORIC-114 in 2021. Cash, cash equivalents and marketable securities totaled $186.6 million as of September 30, 2020.

ORIC Pharmaceuticals reported its Q2 2020 financial results, highlighting the advancement of its pipeline, including ORIC-101 and ORIC-533 programs, and the licensing of ORIC-944. The company's cash position is expected to fund operations into Q4 2022.

ORIC Pharmaceuticals reported first quarter 2020 financial results. The company's cash and cash equivalents totaled $79.4 million as of March 31, 2020. Research and development expenses were $7.3 million, while general and administrative expenses were $1.9 million for the quarter.